Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

A Comprehensive Review of NSAID Cardiovascular Toxicity

A Comprehensive Review of NSAID Cardiovascular Toxicity

Deepan S. Dalal, MD, MPH, Maureen Dubreuil, MD, MS, & David T. Felson, MD, MPH  |  July 18, 2018

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

Filed under:Analgesics Tagged with:acetaminophencelecoxib (Elyxyb)diclofenacIbuprofennaproxenNSAIDsrofecoxib

Video Education: Patient Outreach Effort Offers Education about Cardiovascular Risks

Carina Stanton  |  June 27, 2018

Experts in rheumatoid arthritis, cardiovascular health and education have joined forces to create a video intervention designed to help patients understand their risks for heart attack and stroke, as well as how to reduce these risks. Early research into this educational intervention shows the video is effective…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiovascularEducationpatient educationriskvideo

Submassive pulmonary embolism. Filling defects seen in the pulmonary artery.

Case Report Illustrates Hypercoagulability in Behçet’s Disease

Aiza Tariq, MD, & Jasim Alidina, MD  |  June 21, 2018

Behçet’s disease is a chronic, relapsing and remitting vasculitis with multisystem involvement. Commonly referred to as the Silk Road disease due to its prevalence in the Asian and Mediterranean region of the traditional Silk Road, Behçet’s was first described by Hippocrates as a triad of symptoms—genital and oral ulcers with uveitis—and attributed to links with…

Filed under:Vasculitis Tagged with:Behçet’s diseasehypercoagulabilitypulmonary embolism

Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2018

New research has linked alendronate to reduced cardiovascular death in hip fracture patients…

Filed under:Drug Updates Tagged with:alendronatecardiovascularFDAFractureship fractureJuvenile Arthritis (JIA)polyarticular juvenile idiopathic arthritistocilizumabU.S. Food and Drug Administration (FDA)

IgG4-Related Kidney Disease: Diagnostics, Manifestations, & More

IgG4-Related Kidney Disease: Diagnostics, Manifestations & More

Despina Michailidou, MD, PhD, & Paul Cohen, MD   |  May 17, 2018

Immunoglobin G4-related disease (IgG4-RD) is a rare fibro-inflammatory disease of unknown etiology that has been recently recognized. It can cause fibro-inflammatory masses in almost every organ of the body and is associated with dense lymphoplasmacytic infiltration of IgG4-postitive plasma cells, storiform fibrosis and elevated levels of serum IgG4.1 IgG4-RD is a systemic disease that may…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:fibroinflammatoryIgG4 related diseaseIgG4-RDkidney disease

New Study Raises Cardiovascular Questions about Febuxostat for Gout

Lara C. Pullen, PhD  |  April 30, 2018

New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinolcardiovascularFebuxostathyperuricemiarisk

Autoimmune Inflammation Increases Risk of Heart Disease

Susan Bernstein  |  January 19, 2018

SAN DIEGO—It’s no secret: Autoimmune, inflammatory rheumatic disease raises a patient’s risk of cardiovascular disease (CVD). “Inflammation may affect all aspects of the cardiac structure and function,” said Rekha Mankad, MD, FACC, director of the Women’s Heart Clinic at the Mayo Clinic in Rochester, Minn. Dr. Mankad also oversees a cardio-rheumatology clinic to assess and treat…

Filed under:ConditionsMeeting Reports Tagged with:ACR/ARHP Annual MeetingautoinflammatoryCardiovascular diseaseHeart Diseasepatient care

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee  |  December 19, 2017

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Association of Rheumatology Professionals (ARP)bDMARDbenefitsbiologic disease-modifying antirheumatic drugsCardiovascular diseaseClinicalhipkneeoutcomepatient carereplacementResearchRheumatoid arthritisrheumatologistrheumatologyriskstudytherapy

Kateryna Kon / Shutterstock.com

How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

Ruth Jessen Hickman, MD  |  December 17, 2017

Anemia is common in patients with systemic rheumatic disease, yet it may not get the attention it deserves. Anemia can result from chronic inflammation, treatment side effects or other disease factors, or it may signal an unrelated condition. Although diagnosis and treatment of anemia are sometimes challenging, clinicians must do their utmost to rigorously investigate…

Filed under:Conditions Tagged with:anemiaCauseClinicalDiagnosisinflammationkidneymacrocytic anemiaManagementoutcomepathophysiologypatient careRheumatic Diseaserheumatologistrheumatologysystemic inflammatory syndromeTestTreatmentvitamin deficiency

Older Women Should Not Take Hormones to Prevent Chronic Diseases

Will Boggs MD  |  December 14, 2017

(Reuters Health)— Postmenopausal women should not use hormone therapy to prevent chronic medical conditions, because the risk of significant side effects outweighs the unclear evidence of a benefit, according to a government-backed panel of experts. Most chronic conditions – coronary heart disease, dementia, stroke, fractures, and breast cancer, for example – are more common with…

Filed under:Conditions Tagged with:chronic medical conditionsPostmenopausal hormone therapypostmenopausal womensignificant side effectsU.S. Preventive Services Task Force (USPSTF)

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 64
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences